There were 1,282 patients included, with about half randomized to receive remdesivir and the rest to the control group receiving standard care.
Much evidence has been mixed about the effects of remdesivir, a multiple-use antiviral drug, in people with COVID-19.
The Canadian trial, led by researchers at the University of British Columbia and the Sunnybrook Health Science Center, found that among patients who were not on ventilators at the start of the study, the need for ventilators increased. birth in 8% of patients treated with remdesivir compared with 15% of those receiving standard of care.
In addition, patients treated with remdesivir were able to receive oxygen and mechanical ventilation earlier than patients receiving standard care.
Dr Srinivas Murthy, University of British Columbia, with co-authors write: “The most obvious treatment benefit is preventing the need for mechanical ventilation, suggesting that added value could be for patients with less disease. more severe to avoid progression during hospital stay”.
“This could have important implications for patients and health systems, especially when ICU capacity, mechanical ventilation or oxygen delivery is limited.”
The CATCO trial collected more detailed data than in some other countries and involved patients of many ethnicities, which is particularly important for applications in other countries and multicultural societies. our. The study is also the largest single national remdesivir trial reported to date.
These results add to a larger global trial of how remdesivir could be used in other countries.
“CATCO’s findings are also important and complementary to Solidarity because they help address questions about the generalizability of a large, simple procedure performed across many hospitals and healthcare systems. from low, middle and high income countries”. the authors conclude.